- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | MSD receives FDA approval for Winrevair's updated indication | ||
| 27.10. | Organon CEO stands down amid contraceptive sales malpractice probe | ||
| 27.10. | Guardant and Zephyr AI pair up to advance cancer biomarker development | ||
| 27.10. | GSK targets Syndivia's prostate cancer ADC in £268m buy | ||
| 27.10. | Eli Lilly buys Adverum in eye disease gene therapy punt | ||
| 27.10. | Excellergy eyes IgE therapy space as Xolair nears patent expiry | ||
| 27.10. | Chugai acquires Renalys, enhancing its kidney disease portfolio | ||
| 27.10. | Novartis agrees to buy Avidity Biosciences for $12bn | ||
| 24.10. | UK regulators seize illegal weight loss drugs amid global pricing shake-up | ||
| 24.10. | Dupixent stirs Sanofi's growth as vaccine sales cool | ||
| 24.10. | Lilly and Incyte to seek approval of alopecia JAK inhibitor in children | ||
| 24.10. | Galderma outlays $650m for US manufacturing as Nemluvio sales soar | ||
| 24.10. | EUROAPI's Med4Cure project to strengthen pharma sovereignty | ||
| 24.10. | GSK's Blenrep gains FDA approval for myeloma treatment | ||
| 23.10. | Roche in ongoing discussions with US government over drug pricing, CEO says | ||
| 23.10. | Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls | ||
| 23.10. | Ipsen to buy French biotech company ImCheck Therapeutics | ||
| 23.10. | Biotechs brush off sector headwinds in venture financing rebound | ||
| 23.10. | Alkermes to acquire Avadel for $2.1bn | ||
| 22.10. | Galapagos to shutter cell and gene therapy unit | ||
| 22.10. | Novo Nordisk sees board shakeup amid member exodus | ||
| 22.10. | Ventus and Genentech partner for small-molecule medicine discovery | ||
| 22.10. | Health Canada conditionally approves Gilead Sciences' Lyvdelzi for PBC | ||
| 21.10. | ESMO 2025: Merck KGaA's ADC leapfrogs to Phase III in colorectal cancer | ||
| 21.10. | Gibson, Dunn & Crutcher, White & Case top MEA legal advisers in Q1-Q3 2025 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .